{
    "root": "75d31598-5d66-47f6-91b1-c369193df44b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "medroxyprogesterone acetate",
    "value": "20250522",
    "ingredients": [
        {
            "name": "MEDROXYPROGESTERONE ACETATE",
            "code": "C2QI4IOI2G"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "MINERAL OIL",
            "code": "T5L8T28FGP"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": "medroxyprogesterone acetate tablets indicated treatment secondary amenorrhea abnormal uterine bleeding due hormonal imbalance absence organic pathology , fibroids uterine cancer . also indicated prevention endometrial hyperplasia nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets .",
    "contraindications": null,
    "warningsAndPrecautions": "medroxyprogesterone acetate tablets available following strengths package sizes : 2.5 mg tablets bottles 100 : ndc 59762-0055-1 ( scored , round , orange , imprinted provera 2.5 ) bottles 1000 : ndc 59762-0055-2 ( scored , round , orange , imprinted provera 2.5 ) 5 mg tablets bottles 100 : ndc 59762-0058-1 ( scored , round , blue , imprinted provera 5 ) bottles 1000 : ndc 59762-0058-2 ( scored , round , blue , imprinted provera 5 ) 10 mg tablets bottles 100 : ndc 59762-0056-1 ( scored , round , white , imprinted provera 10 ) bottles 1000 : ndc 59762-0056-2 ( scored , round , white , imprinted provera 10 )",
    "adverseReactions": "mpa tablets contraindicated women following conditions : 1. undiagnosed abnormal genital bleeding . 2. known , suspected , history breast cancer . 3. known suspected estrogen- progesterone-dependent neoplasia . 4. active dvt , pe , history conditions . 5. active arterial thromboembolic disease ( example , stroke myocardial infarction ) , history conditions . 6. known anaphylactic reaction angioedema mpa . 7. known liver impairment disease . 8. known suspected pregnancy .",
    "indications_original": "Medroxyprogesterone acetate tablets are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.",
    "warningsAndPrecautions_original": "Medroxyprogesterone acetate tablets are available in the following strengths and package sizes: \n                  \n                     2.5 mg tablets\n                  \n                  Bottles of 100: NDC 59762-0055-1 (scored, round, orange, imprinted PROVERA 2.5)Bottles of 1000: NDC 59762-0055-2 (scored, round, orange, imprinted PROVERA 2.5)\n                  \n                     5 mg tablets\n                  \n                  Bottles of 100: NDC 59762-0058-1 (scored, round, blue, imprinted PROVERA 5)Bottles of 1000: NDC 59762-0058-2 (scored, round, blue, imprinted PROVERA 5)\n                  \n                     10 mg tablets\n                  \n                  Bottles of 100: NDC 59762-0056-1 (scored, round, white, imprinted PROVERA 10)Bottles of 1000: NDC 59762-0056-2 (scored, round, white, imprinted PROVERA 10)",
    "adverseReactions_original": "MPA tablets is contraindicated in women with any of the following conditions:\n                  1. Undiagnosed abnormal genital bleeding.\n                  2. Known, suspected, or history of breast cancer.\n                  3. Known or suspected estrogen- or progesterone-dependent neoplasia.\n                  4. Active DVT, PE, or a history of these conditions.\n                  5. Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions.\n                  6. Known anaphylactic reaction or angioedema to MPA.\n                  7. Known liver impairment or disease.\n                  8. Known or suspected pregnancy."
}